|Bid||175.72 x 4000|
|Ask||181.97 x 900|
|Day's Range||178.20 - 181.54|
|52 Week Range||166.30 - 210.19|
|Beta (3Y Monthly)||0.95|
|PE Ratio (TTM)||14.23|
|Forward Dividend & Yield||5.80 (3.25%)|
|1y Target Est||N/A|
Gilead Sciences should acquire Celgene's psoriasis drug Otezla, but only for less than $9.6 billion, analysts said Thursday. Celgene is divesting Otezla ahead of its Bristol-Myers merger.
Japanese drugmaker Eisai is investing $120 million over three years in an Alzheimer's research center — a 20 percent increase over the funding Eisai originally had allocated for the facility.
Amgen (AMGN) and Novartis (NVS) discontinue two Alzheimer's disease studies. Alzheimer's has always been a highly challenging area with many studies failing.
A drug to treat Alzheimer's disease is increasingly proving elusive, despite billions of dollars spent on research and development. Johnson & Johnson (NYSE: JNJ )'s Janssen unit; Merck & Co., Inc. (NYSE: ...
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Dow Jones futures: Illumina stock and profitable marijuana stock Innovative Industrial Properties fell late on news. An Amgen-Novartis Alzheimer's drug failed. Hookipa Pharma soared.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on July 11) Enlivex Therapeutics Ltd (NASDAQ: ENLV ) GALAPAGOS ...
Amgen Inc. and Novartis AG announced Thursday afternoon that they will discontinue a study into a potential Alzheimer's disease prevention therapy after patients in the study showed worsening conditions. "An assessment of unblinded data during a regular pre-planned review identified worsening in some measures of cognitive function," the companies said in a joint announcement. "The sponsors concluded that the potential benefit for participants in the studies did not outweigh the risk." The phase 2/3 study, performed in conjunction with Banner Alzheimer's Institute, was testing the BACE1 inhibitor CNP520, or umibecestat, which is an amyloid-focused drug. Biogen Inc. failed in testing of an amyloid-focused drug earlier this year, leading some to predict that focusing on the sticky protein found in the brain could be a losing route to a drug for the debilitating neurodegenerative disease. "We still believe amyloid plays an important but complex role in Alzheimer's disease," Amgen executive David Reese said in Thursday's announcement. Novartis shares were down 1.5% in after-hours trading Thursday, while Amgen shares were not moving after the announcement.
The drug companies provide rebates to PBMs in exchange for distributing their products.
Amgen and Novartis have closed two studies trying to find drugs for Alzheimer’s disease, dealing another blow to the millions of patients left waiting for a treatment for the neurodegenerative disorder. The pharmaceutical companies, along with their partner, the research centre Banner Alzheimer’s Institute, said that some patients on the trials had shown a worsening — rather than the hoped for improvement — in cognitive function. The decision comes after Biogen, a neuroscience-focused biotech company, closed down its Alzheimer’s drug trial with Japanese company Eisai in April, after they found the drug was not going to be effective.
Mirati (MRTX) inks a clinical collaboration with Novartis to evaluate the combination of the former's MRTX849 and the latter's SHP2 inhibitor, TNO155, in patients with advanced solid tumors.
The recent ruling by a federal court against the Trump regime's decree to disclose the price labels of drugs in TV adverts resumes the spotlight on drug pricing.
With key drugs losing exclusivity, key drug makers are poised to face deep trouble since their sales are mostly dependent on a single drug.
Roche (RHHBY) presents new positive data on Hemlibra, reinforcing its efficacy and safety. Moreover, the deadline of the impending merger with Spark has been extended.
A federal judge handed a big win to big pharma on Monday, saying a regulation that required drug companies to disclose drug prices in television ads was invalid.